PPARG and metabolic dysfunction-associated steatotic liver disease: ,49 However, it has been shown before that an induction of PPARγ2 is associated with the development of MASLD in various rodent models10,53 and that targeting PPARγ2 with the PPARγ antagonist GW9662 may attenuate the development of MASLD.10